Testing has demonstrated Betadine's strong in-vitro virucidal activity, killing 99.99% of the SARS-CoV-2 virus in 30 seconds. The products subjected to testing were: Betadine antiseptic products, namely Solution (10% PVP-I), Skin Cleanser (7.5% PVP-I), Gargle and Mouthwash (1.0% PVP-I) and Throat Spray (0.45% PVP-I).
The research has been published in the respected Infectious Disease and Therapy Journal on 08 July 2020.
The study conducted at Duke-NUS is complemented by Laboratory testing completed at the Tropical Infectious Diseases Research and Education Center (TIDREC) at the University of Malaya, Malaysia, that also demonstrated strong in-vitro virucidal activity, with the tested product Betadine Gargle and Mouthwash (1.0% PVP-I) killing 99.99% of the SARS-CoV-2 virus in 15 seconds.
The TIDREC research has been accepted by the British Dental Journal and was published as a Letter on 26 June 2020. The journal is published by Springer Nature on behalf of the British Dental Association.
Previously, Betadine antiseptic products containing povidone iodine (PVP-I) have been proven effective in vitro against a wide range of viruses, including coronaviruses that have caused major outbreaks such as Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome.
The Betadine antiseptic range contains Povidone-iodine (PVP-I), which is highly effective against a wide range of microorganisms, including bacteria, viruses and fungi and is typically used in hospitals.
Mundipharma's independent associated companies are privately owned entities covering the world's pharmaceutical markets.
Mundipharma offers novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.
The Betadine range of products have been trusted by hospitals and consumers around the world for over 60 years to prevent and treat infections.
AstraZeneca's Fasenra misses primary endpoint in Phase III COPD trial
Hemogenyx reports positive safety and early efficacy data from third patient in CAR-T trial
Sanofi reports positive phase 2a results for brivekimig in hidradenitis suppurativa
GSK commits USD30bn to US R&D and manufacturing expansion
Neurocrine Biosciences announces presentation of Osavampator Phase 2 data at Psych Congress 2025
Ascletis presents ASC30 study results at EASD Annual Meeting
Three WuXi Biologics manufacturing facilities receive GMP certification from Turkish regulator
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial